While the guaiac-based fecal occult blood test (FOBT) has been found to be effective for population screening for colorectal cancer, immunochemical FOBT (IFOBT) deserves attention as offering superior sensitivity, usually with no major loss of specificity. A great deal of interest has been concentrated on sigmoidoscopy or colonoscopy as alternatives but medical capacity is a major problem with ...

Colorectal cancer causes significant morbidity and mortality and remains the second most common cause of cancer-related death in the United States. A number of screening approaches have been shown to decrease colon cancer–related mortality and are cost-effective. In this review, we discuss available screening approaches and suggest strategies to implement effective screening using the current t...

BACKGROUND Recommended colorectal cancer (CRC) screening tests for adults ages 50 to 75 years include home fecal occult blood tests (FOBT), sigmoidoscopy with FOBT, and colonoscopy. A newer test, computed tomographic (CT) colonography, has been recommended by some, but not all, national organizations. METHODS We analyzed 2010 National Health Interview Survey data, including new CT colonograph...

BACKGROUND There is no agreement on the best data source for measuring colorectal cancer (CRC) screening. Medicare claims have been used to measure CRC testing but the validity of using claims to measure fecal occult blood tests (FOBT) has not been established. METHODS We compared ascertainment of FOBT among three data sources: self-reports, Medicare claims, and medical records. Data were col...

AIM Current fecal screening tools for colorectal cancer (CRC), such as fecal occult blood tests (FOBT), are limited by their low sensitivity. Calgranulin B (CALB) was previously reported as a candidate fecal marker for CRC. This study investigated whether a combination of the FOBT and fecal CALB has increased sensitivity and specificity for a diagnosis of CRC. MATERIALS AND METHODS Patients w...

OBJECTIVE To determine whether medication interventions enhance the sensitivity and specificity of guaiac-based fecal occult blood testing (FOBT) when screening for colorectal cancer (CRC). DATA SOURCES We searched PubMed-MEDLINE, CINAHL, and the Cochrane databases using the MeSH headings occult blood, feces/analysis, and guaiac/analysis, linking them to variations of anticoagulants, heparin,...

BACKGROUND Strong evidence exists that screening with fecal occult blood testing (FOBT), sigmoidoscopy, or colonoscopy reduces the number of deaths from colorectal cancer (CRC). The percentage of the population up-to-date with recommended CRC screening increased from 54% in 2002 to 65% in 2010, primarily through increased use of colonoscopy. METHODS Data from the 2012 Behavioral Risk Factor S...

Primary care physicians (PCPs) often do not recommend complete diagnostic evaluation (CDE; i.e., diagnostic colonoscopy or the combination of flexible sigmoidoscopy and barium enema X-ray procedures) for patients with an abnormal screening fecal occult blood test (FOBT+) result. Information is needed to understand why PCPs do not recommend CDE. In the spring of 1994, a telephone survey was carr...

Screening programs for colorectal cancer (CRC) are standard in most developed countries because they reduce mortality and cost-effective. Within them, colonoscopy allows to directly visualize the colon remove neoplastic lesions. However, it is an expensive exam with low adherence asymptomatic individuals. The fecal occult blood test (FOBT) a low-cost risk-free method user, which results high ra...

Colorectal cancer (CRC) is a leading cause of morbidity and mortality globally.1 Survival the disease strongly associated with stage at diagnosis, 5-year survival rates reaching more than 90% when diagnosed I, compared just 10% IV.2 Fortunately, CRC amenable to screening, which enables detection CRCs early, treatable stages, prevention via removal premalignant polyps.3 Results from national sur...